Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: hospital

Baricitinib May Exhibit Better Efficacy Than Adalimumab for RA

Michele B. Kaufman, PharmD, BCGP  |  March 7, 2017

In a recent study, baricitinib proved more effective than adalimumab in treating adults with RA through 52 weeks…

Filed under:Drug Updates Tagged with:baricitinibRheumatoid Arthritis (RA)

What Rheumatologists Wish Their Colleagues Knew: Managing Skin Disease & Comorbidities

Richard Quinn  |  March 3, 2017

From treating rashes to uncovering a case of osteoarthritis, dermatologists and rheumatologists can work together in a variety of ways to improve patient care, says Joseph F. Merola, MD, MMSc…

Filed under:ConditionsPsoriatic ArthritisSystemic Sclerosis Tagged with:DermatologyPsoriasisPsoriatic Arthritisrheumatologistskinskin disease

ACR Releases New Position Statements on Site of Service & Compounding

Mary Beth Nierengarten  |  March 1, 2017

Patient Safety & Site of Service for Biologics Although emphasizing its strong support for the use of biologic agents as necessary treatments for rheumatic diseases, the ACR Board of Directors continues to be concerned about the safe delivery of these agents, given the potential for associated adverse events and infusion reactions. In a position statement…

Filed under:Biologics/DMARDsLegislation & Advocacy Tagged with:biologic infusionsdrug compoundingposition statementquinacrine

Certolizumab Pegol Promising for Plaque Psoriasis in Phase 3 Trial

Michele B. Kaufman, PharmD, BCGP  |  March 1, 2017

Certolizumab pegol has proved safe and effective for treating patients with plaque psoriasis in a Phase 3 clinical trial…

Filed under:Biologics/DMARDsConditionsDrug UpdatesSystemic Sclerosis Tagged with:Certolizumab Pegoletanerceptplaque psoriasis

FDA Considers Tocilizumab for GCA & Piclidenoson Enters Phase 3 Trial for RA, Psoriasis

Michele B. Kaufman, PharmD, BCGP  |  February 27, 2017

The FDA is considering a supplemental biologics license application for tocilizumab to treat giant cell arteritis…

Filed under:Biologics/DMARDsDrug Updates Tagged with:FDAFood and Drug AdministrationGCAgiant cell arteritis (GCA)piclidenosontocilizumab

Peripheral Helper Cells May Provide Clue to RA Pathology

Lara C. Pullen, PhD  |  February 27, 2017

Research has identified a subset of T cells, peripheral helper (TPH) cells, which may promote pathological B cell responses and antibody production in patients with seropositive RA. TPH cells also express chemokine receptors, enabling them to infiltrate inflamed parts of the body and stimulate B cells to produce antibodies…

Filed under:ConditionsRheumatoid Arthritis Tagged with:B cellsperipheral helper cellsRheumatoid Arthritis (RA)seropositive RAT cell

Online Treatment Reduces Chronic Knee Pain from Arthritis

Shereen Lehman  |  February 22, 2017

(Reuters Health)—A web-based program of exercise and coping skills training improves both function and pain in arthritic knees, a new study suggests. This kind of online therapy can greatly improve access to effective, nonsurgical and non-drug relief for people with osteoarthritis of the knee, researchers say. “Osteoarthritis is a leading cause of chronic knee pain…

Filed under:ConditionsOsteoarthritis and Bone DisordersProfessional Topics Tagged with:Arthritisknee painonline therapyPainCOACHtelemedicine

Volatility of the Gut Microbiome Tied to IBD

Marilynn Larkin  |  February 21, 2017

NEW YORK (Reuters Health)—Fluctuations in the gut microbiome over time could underlie inflammatory bowel disease (IBD), including Crohn’s and ulcerative colitis, researchers suggest. “Both the state and the dynamics of the human gut microbiome in healthy individuals are highly personalized. Although cross-sectional studies have revealed dysbiosis of the gut microbiome in IBD, little is known…

Filed under:ConditionsOther Rheumatic Conditions Tagged with:Crohn's diseasegut microbiomeMicrobiomeulcerative colitis

Physician’s Choice: Factors That Influence First- & Second-Line Biologic Therapy in RA Patients

Michele B. Kaufman, PharmD, BCGP  |  February 20, 2017

In patients with RA, age and higher rates of comorbidity are influential in selecting and changing treatments…

Filed under:Biologics/DMARDsDrug Updates Tagged with:abataceptbiologic drugsBiologicsRheumatoid Arthritis (RA)TNF inhibitorstocilizumab

Celecoxib Is a Safe Treatment for Arthritis

Lara C. Pullen, PhD  |  February 20, 2017

A study compared celecoxib with ibuprofen and naproxen to determine its cardiovascular safety, as well as gastrointestinal and renal outcomes, in patients with rheumatoid arthritis and osteoarthritis. The results showed that celecoxib met all prespecified noninferiority requirements and is as safe as other non-selective NSAIDs…

Filed under:Drug Updates

  • « Previous Page
  • 1
  • …
  • 190
  • 191
  • 192
  • 193
  • 194
  • …
  • 323
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences